MDLZ Earnings

MDLZ reported its earnings on 2026-02-03, showcasing a revenue of 10.50B against an estimate of 10.33B, resulting in a 1.61% surprise. The EPS was 0.72, surpassing the expected 0.7 by 2.86%. The stock experienced a -0.12% price change on the earnings day and a 2.12% change over the next five days, reflecting market reactions to the results.

Following MDLZ's earnings announcement on 2026-02-03, the stock price moved by -0.12% on the day of the release. Over the subsequent five days, it saw a 2.12% change. Historically, MDLZ's stock price tends to shift by an average of -1.17% in the 10 days leading up to earnings and -0.93% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate MDLZ's annual revenue to reach 9.94B, while the EPS is projected at 0.79. These estimates reflect recent revisions, with revenue estimates revised downward by -0.03% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MDLZ's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.03%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MDLZ's stock price typically moves by -1.17% in the 10 days before its earnings and -0.93% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.79 and revenue of 9.94B.

The earnings call summary presents a mixed outlook. While there are positive elements such as strategic investments and diversification, challenges in North American markets and cautious guidance due to cocoa price fluctuations create uncertainties. The Q&A session reveals management's lack of clarity on competitive reactions and specific strategies, which tempers optimism. Overall, the sentiment is neutral as positive long-term strategies are offset by short-term market challenges and lack of detailed guidance.